Skip to main content
PharmaBlock Sciences (Nanjing), Inc. logo

PharmaBlock Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 300725 ISIN · CNE1000035K5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2024-05-10 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300725

About PharmaBlock Sciences (Nanjing), Inc.

https://www.pharmablock.com

PharmaBlock Sciences (Nanjing), Inc. specializes in the design and manufacture of innovative building blocks and provides integrated chemistry services for drug discovery and development. The company offers a comprehensive portfolio of structurally diverse scaffolds and intermediates used to enhance the efficiency of medicinal chemistry. Its core capabilities include process research and development, scale-up production, and commercial-scale manufacturing under CDMO frameworks. By utilizing advanced chemical technologies and a vast library of unique chemical entities, the company supports global biotechnology and pharmaceutical organizations in streamlining their research pipelines and optimizing the transition from discovery to clinical development and commercialization.

Recent filings

Filing Released Lang Actions
关于董事会提议向下修正可转换公司债券转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the board of directors of Nanjing Yaoshi Technology Co., Ltd. regarding a proposal to downward adjust the conversion price of its convertible bonds. It details the background of the convertible bonds issuance, previous adjustments, the conditions triggering the current proposed adjustment, and the procedural steps including submission to the shareholders' meeting for approval. The document is a formal disclosure of a corporate action related to capital structure and convertible bond terms, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the proposal and related corporate decisions. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as convertible bond price adjustments.
2024-05-10 Chinese
第三届董事会第三十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 31st meeting of the 3rd Board of Directors of Nanjing Yaoshi Technology Co., Ltd. It details the meeting's convening, voting results, and proposals to be submitted to the shareholders' meeting, including a proposal to adjust the convertible bond conversion price and to convene an extraordinary general meeting. The document is not a full report but a board meeting resolution announcement. It does not contain financial statements or detailed financial data, nor is it a shareholder meeting material or voting result announcement. It fits best under Board/Management Information (MANG) as it relates to board decisions and management proposals.
2024-05-10 Chinese
关于召开2024年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2024 first extraordinary general meeting (临时股东大会) of Nanjing Pharmablock Technology Co., Ltd. It includes information about the meeting date, time, location, voting procedures (both onsite and online), registration details, and agenda items for shareholder approval. It does not contain financial statements, audit opinions, or earnings data. It is not a report of voting results but a notice to shareholders about the meeting and how to participate. The document length is about 4977 characters, which is consistent with a detailed meeting notice. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or about the Annual or Extraordinary General Meeting, including notices of meetings.
2024-05-10 Chinese
华泰联合证券有限责任公司关于南京药石科技股份有限公司2023年度持续督导的培训报告
Audit Report / Information Classification · 90% confidence The document is a training report from Huatai United Securities Co., Ltd. regarding continuous supervision training for Nanjing Yaoshi Technology Co., Ltd. in 2023. It details the training content, personnel involved, and outcomes related to regulatory compliance and corporate governance. The document is relatively short (1106 characters) and focuses on a specific training activity rather than financial results, audit opinions, or management changes. It is not an announcement of a report publication but a standalone report on training activities. This fits best under the category of Audit Report / Information (AR), as it relates to regulatory compliance and supervisory activities rather than a full annual report or other categories.
2024-05-08 Chinese
华泰联合证券有限责任公司关于南京药石科技股份有限公司2023年度现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度现场检查报告" (2023 Annual On-site Inspection Report) issued by Huatai United Securities Co., Ltd. regarding Nanjing Yaoshi Technology Co., Ltd. It references regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange guidelines. The content details the on-site inspection of company governance, internal controls, information disclosure, protection mechanisms, use of raised funds, performance, shareholder commitments, and other important matters. The document is a detailed inspection report rather than a general annual report or financial statement. It is not an announcement or a brief summary but a substantive report on regulatory compliance and internal controls. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of regulatory inspections. The document length is 4125 characters, which is substantive enough to be a report rather than a mere announcement. Therefore, the appropriate classification is AR with high confidence.
2024-05-08 Chinese
华泰联合证券有限责任公司关于南京药石科技股份有限公司2023年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度持续督导跟踪报告" (2023 Annual Continuous Supervision Follow-up Report) issued by the sponsoring institution 华泰联合证券有限责任公司 regarding 南京药石科技股份有限公司. It details the sponsor's ongoing supervision activities, including information disclosure review, governance oversight, fundraising supervision, and other compliance checks. The document is a formal report on the sponsor's continuous monitoring work rather than a full annual report or financial statement. It does not contain comprehensive financial data or management discussion and analysis typical of Annual Reports (10-K) or Interim Reports (IR). It is also not an announcement or a brief notice but a substantive report on supervision activities. This type of document aligns with the category of Audit Report / Information (AR), which includes standalone audit or supervision reports and related regulatory compliance information. The document length is 2356 characters, which is substantive but not overly long, consistent with an audit or supervision report rather than a full annual report. Therefore, the best classification is AR with high confidence.
2024-05-08 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.